Comparison of humans versus mobile phone-powered artificial intelligence for the diagnosis and management of pigmented skin cancer in secondary care: a multicentre, prospective, diagnostic, clinical trial

Autor: Scott W Menzies, ProfPhD, Christoph Sinz, MD, Michelle Menzies, BSc, Serigne N Lo, PhD, William Yolland, BSc, Johann Lingohr, BSc, Majid Razmara, PhD, Philipp Tschandl, PhD, Pascale Guitera, ProfPhD, Richard A Scolyer, ProfMD, Florentina Boltz, MD, Liliane Borik-Heil, MD, Hsien Herbert Chan, MD, David Chromy, MD, David J Coker, MD, Helena Collgros, MD, Maryam Eghtedari, MD, Marina Corral Forteza, MD, Emily Forward, MD, Bruna Gallo, MD, Stephanie Geisler, MD, Matthew Gibson, MMed, Amelie Hampel, MD, Genevieve Ho, MD, Laura Junez, MD, Philipp Kienzl, PhD, Arthur Martin, MD, Fergal J Moloney, MD, Amanda Regio Pereira, MD, Julia Maria Ressler, MD, Susanne Richter, MD, Katharina Silic, MD, Thomas Silly, MD, Michael Skoll, MD, Julia Tittes, MD, Philipp Weber, MD, Wolfgang Weninger, ProfPhD, Doris Weiss, MD, Ping Woo-Sampson, MD, Catherine Zilberg, MD, Harald Kittler, MD

Publikováno v: The Lancet: Digital Health, Vol 5, Iss 10, Pp e679-e691 (2023)

Summary: Background: Diagnosis of skin cancer requires medical expertise, which is scarce. Mobile phone-powered artificial intelligence (AI) could aid diagnosis, but it is unclear how this technology performs in a clinical scenario. Our primary aim w

Externí odkaz: https://doaj.org/article/bb536ef03af64214ad529982414e2889

Predicting Sentinel Node Status in Patients With Melanoma: Does Gene Expression Profiling Improve Accuracy?

Autor: Varey AHR; Alexander H. R. Varey, MBChB, PhD, Melanoma Institute Australia and Faculty of Medicine and Health, The University of Sydney, Sydney, and Department of Plastic Surgery, Westmead Hospital, Westmead, NSW, Australia; Serigne N. Lo, PhD, Melanoma Institute Australia and Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Richard A. Scolyer, PhD, Melanoma Institute Australia and Faculty of Medicine and Health, The University of Sydney, Sydney, and Department of Tissue Oncology and Diagnostic Pathology, Royal Prince Alfred Hospital and NSW Health Pathology, Camperdown, NSW, Australia; and John F. Thompson, MD, Melanoma Institute Australia and Faculty of Medicine and Health, The University of Sydney, Sydney, and Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia., Lo SN; Alexander H. R. Varey, MBChB, PhD, Melanoma Institute Australia and Faculty of Medicine and Health, The University of Sydney, Sydney, and Department of Plastic Surgery, Westmead Hospital, Westmead, NSW, Australia; Serigne N. Lo, PhD, Melanoma Institute Australia and Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Richard A. Scolyer, PhD, Melanoma Institute Australia and Faculty of Medicine and Health, The University of Sydney, Sydney, and Department of Tissue Oncology and Diagnostic Pathology, Royal Prince Alfred Hospital and NSW Health Pathology, Camperdown, NSW, Australia; and John F. Thompson, MD, Melanoma Institute Australia and Faculty of Medicine and Health, The University of Sydney, Sydney, and Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia., Scolyer RA; Alexander H. R. Varey, MBChB, PhD, Melanoma Institute Australia and Faculty of Medicine and Health, The University of Sydney, Sydney, and Department of Plastic Surgery, Westmead Hospital, Westmead, NSW, Australia; Serigne N. Lo, PhD, Melanoma Institute Australia and Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Richard A. Scolyer, PhD, Melanoma Institute Australia and Faculty of Medicine and Health, The University of Sydney, Sydney, and Department of Tissue Oncology and Diagnostic Pathology, Royal Prince Alfred Hospital and NSW Health Pathology, Camperdown, NSW, Australia; and John F. Thompson, MD, Melanoma Institute Australia and Faculty of Medicine and Health, The University of Sydney, Sydney, and Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia., Thompson JF; Alexander H. R. Varey, MBChB, PhD, Melanoma Institute Australia and Faculty of Medicine and Health, The University of Sydney, Sydney, and Department of Plastic Surgery, Westmead Hospital, Westmead, NSW, Australia; Serigne N. Lo, PhD, Melanoma Institute Australia and Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Richard A. Scolyer, PhD, Melanoma Institute Australia and Faculty of Medicine and Health, The University of Sydney, Sydney, and Department of Tissue Oncology and Diagnostic Pathology, Royal Prince Alfred Hospital and NSW Health Pathology, Camperdown, NSW, Australia; and John F. Thompson, MD, Melanoma Institute Australia and Faculty of Medicine and Health, The University of Sydney, Sydney, and Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.

Publikováno v: JCO precision oncology [JCO Precis Oncol] 2020 Nov; Vol. 4, pp. 990-991.